A new paradigm for targeting mutant p53 tumours [ 2017 - 2020 ]

Research Grant

Researchers: Prof Wayne Phillips (Principal investigator) ,  Dr Carleen Cullinane ,  Dr Nicholas Clemons ,  Prof Ygal Haupt

Brief description Over half of all cancers contain mutations in a gene called TP53, also known as the “guardian of the genome”. Mutation of TP53 provides tumour cells with a growth advantage, and leads to resistance to chemotherapy and poor outcomes for patients. We have identified a potential “Achilles heel” in cancers with TP53 mutations. In this project we will establish a new paradigm for treating tumours with TP53 mutations that will be applicable to a large number of patients across all types of cancer.

Funding Amount $AUD 923,701.69

Funding Scheme Project Grants

Notes Standard Project Grant